EASL recommendations on treatment of hepatitis C 2014

Journal of Hepatology

Volumn 61, Issue 2, 2014, Pages 373-395

  Pawlotsky, Jean Michel ^b   Aghemo, Alessio ^b   Dusheiko, Geoffrey ^b   Forns, Xavier ^b   Puoti, Massimo ^b   Sarrazin, Christophe ^b  

^a EASL Office   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BOCEPREVIR; DACLATASVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; VIRUS RNA;

CHRONIC LIVER DISEASE; DEVELOPMENT; DIAGNOSTIC PROCEDURE; DRUG DEPENDENCE; EUROPEAN MEDICINES AGENCY; FOLLOW UP; GRAFT RECIPIENT; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEMODIALYSIS; HEMOGLOBINOPATHY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MEDICAL SOCIETY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; DRUG COMBINATION; GENOTYPE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C; HUMANS; RNA, VIRAL;

EID: 84904707593     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.05.001     Document Type: Article

References (98)

1. D. Lavanchy Evolving epidemiology of hepatitis C virus Clin Microbiol Infect 17 2011 107 115
2. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 55 2011 245 264
3. N. Antaki, A. Craxi, S. Kamal, R. Moucari, S. Van der Merwe, and S. Haffar et al. The neglected hepatitis C virus genotypes 4, 5, and 6: an international consensus report Liver Int 30 2010 342 355
4. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem et al. Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
5. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej et al. Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
6. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski et al. Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
7. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts et al. Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
8. S. Chevaliez, and J.M. Pawlotsky Diagnosis and management of chronic viral hepatitis: antigens, antibodies, and viral genomes Best Pract Res Clin Gastroenterol 22 2008 1031 1048
9. S. Kamili, J. Drobeniuc, A.C. Araujo, and T.M. Hayden Laboratory diagnostics for hepatitis C virus infection Clin Infect Dis 55 2012 S43 S48
10. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, and L. Leclere et al. Twelve weeks post-treatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
11. M.G. Swain, M.Y. Lai, M.L. Shiffman, W.G. Cooksley, S. Zeuzem, and D.T. Dieterich et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
12. L. Castera, G. Sebastiani, B. Le Bail, V. de Ledinghen, P. Couzigou, and A. Alberti Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C J Hepatol 52 2010 191 198
13. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, and M. Haaser et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350
14. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice PLoS One 4 2009 e8209
15. M.T. Huisman, J. Snoeys, J. Monbaliu, M.A. Martens, V.J. Sekar, and A. Raoof In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters Hepatology 52 2010 461A 462A
16. S. Ouwerkerk-Mahadevan, A. Simion, S. Mortier, M. Peeters, and M. Beumont No clinically significant interaction between the investigational HCV protease inhibitor TMC435 and the immunosuppressives cyclosporine and tacrolimus Hepatology 56 2012 [231A-231A]
17. EASL Clinical Practice Guidelines Management of hepatitis C virus infection J Hepatol 60 2014 392 420
18. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon et al. Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
19. I. Jacobson, G.J. Dore, G.R. Foster, M.W. Fried, M. Radu, and V.V. Rafalskiy et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial J Hepatol 58 2013 S574-S574
20. M. Manns, P. Marcellin, F. Poordad, E. de Araujo, M. Buti, and Y. Horsmans et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial J Hepatol 58 2013 S568-S568
21. F. Poordad, M.P. Manns, P. Marcellin, E.S.A. de Araujo, M. Buti, and Y. Horsmans et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a Phase III trial Gastroenterology 144 2013 S151-S151
22. E. Lawitz, X. Forns, S. Zeuzem, E. Gane, J.P. Bronowicki, and P. Andreone et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a Phase III trial Gastroenterology 144 2013 S151-S151
23. C. Hezode, G.M. Hirschfield, W. Ghesquiere, W. Sievert, M. Rodriguez-Torres, and S.D. Shafran et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results Hepatology 56 2012 553A 554A
24. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
25. A. Osinusi, E.G. Meissner, Y.J. Lee, D. Bon, L. Heytens, and A. Nelson et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
26. J.P. Lalezari, D.R. Nelson, R.H. Hyland, M. Lin, S.J. Rossi, and W.T. Symonds et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment-naive patients with HCV infection: the QUANTUM study J Hepatol 58 2013 S346-S346
27. M.S. Sulkowski, M. Rodriguez-Torres, J.P. Lalezari, W.J. Fessel, K. Mounzer, and M.C. Shuhart et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1) Hepatology 58 2013 313A 314A
28. I. Jacobson, R.H. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and M. Sulkowski et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study Hepatology 58 2013 1379A
29. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
30. R.J. Fontana, E.A. Hughes, M. Bifano, H. Appelman, D. Dimitrova, and R. Hindes et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C Am J Transplant 13 2013 1601 1605
31. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
32. S. Zeuzem, G. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, and R.H. Hyland et al. Sofosbuvir plus ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial Hepatology 58 2013 733A
33. E. Lawitz, F. Poordad, D.M. Brainard, R.H. Hyland, D. An, and W.T. Symonds et al. Sofosbuvir in combination with PegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study Hepatology 58 2013 1380A
34. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, and A.M. Sheikh et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408
35. P.J. Ruane, D. Ain, J. Riad, R.G. Meshrekey, R. Stryker, and P.R. Wolfe et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian ancestry Hepatology 58 2013 736A
36. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31
37. C. Sarrazin, M.L. Shiffman, S.J. Hadziyannis, A. Lin, G. Colucci, and H. Ishida et al. Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy J Hepatol 52 2010 832 838
38. J. Vermehren, A. Kau, B.C. Gartner, R. Gobel, S. Zeuzem, and C. Sarrazin Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification J Clin Microbiol 46 2008 3880 3891
39. M.W. Fried Side effects of therapy of hepatitis C and their management Hepatology 36 2002 S237 S244
40. M.W. Fried, M.L. Shiffman, K.R. Reddy, C. Smith, G. Marinos, and F.L. Goncales Jr. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
41. S.J. Hadziyannis, H. Sette Jr., T.R. Morgan, V. Balan, M. Diago, and P. Marcellin et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
42. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
43. M.L. Shiffman, J. Salvatore, S. Hubbard, A. Price, R.K. Sterling, and R.T. Stravitz et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha Hepatology 46 2007 371 379
44. A. Soza, J.E. Everhart, M.G. Ghany, E. Doo, T. Heller, and K. Promrat et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C Hepatology 36 2002 1273 1279
45. N.H. Afdhal, D.T. Dieterich, P.J. Pockros, E.R. Schiff, M.L. Shiffman, and M.S. Sulkowski et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study Gastroenterology 126 2004 1302 1311
46. P.J. Pockros, M.L. Shiffman, E.R. Schiff, M.S. Sulkowski, Z. Younossi, and D.T. Dieterich et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy Hepatology 40 2004 1450 1458
47. M.S. Sulkowski, F. Poordad, M.P. Manns, J.P. Bronowicki, K. Rajender Reddy, and S.A. Harrison et al. Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial Hepatology 57 2013 974 984
48. S.M. Alavian, and S.H. Aalaei-Andabili Education by a nurse increases the adherence to therapy in chronic hepatitis C patients Clin Gastroenterol Hepatol 10 2012 203
49. J.L. Rodis, and P. Kibbe Evaluation of medication adherence and quality of life in patients with hepatitis C virus receiving combination therapy Gastroenterol Nurs 33 2010 368 373
50. B.S. Anand, S. Currie, E. Dieperink, E.J. Bini, H. Shen, and S.B. Ho et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study Gastroenterology 130 2006 1607 1616
51. P. Bruggmann, M. Dampz, T. Gerlach, L. Kravecz, and L. Falcato Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study Drug Alcohol Depend 110 2010 167 171
52. C. Le Lan, A. Guillygomarc'h, H. Danielou, G. Le Dreau, F. Laine, and C. Vedeilhie et al. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse J Hepatol 56 2012 334 340
53. L. Siu, J. Foont, and J.R. Wands Hepatitis C virus and alcohol Semin Liver Dis 29 2009 188 199
54. M. Backmund, K. Meyer, and B.R. Edlin Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users Clin Infect Dis 39 2004 1540 1543
55. S.L. Currie, J.C. Ryan, D. Tracy, T.L. Wright, S. George, and R. McQuaid et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus Drug Alcohol Depend 93 2008 148 154
56. O. Dalgard Follow-up studies of treatment for hepatitis C virus infection among injection drug users Clin Infect Dis 40 2005 S336 S338
57. J. Grebely, E. Knight, T. Ngai, K.A. Genoway, J.D. Raffa, and M. Storms et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users J Gastroenterol Hepatol 25 2010 1281 1284
58. J. Grebely, S.T. Pham, G.V. Matthews, K. Petoumenos, R.A. Bull, and B. Yeung et al. Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection Hepatology 55 2012 1058 1069
59. R.J. Barnard, J.A. Howe, R.A. Ogert, S. Zeuzem, F. Poordad, and S.C. Gordon et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies Virology 444 2013 329 336
60. F. McPhee, D. Hernandez, F. Yu, J. Ueland, A. Monikowski, and A. Carifa et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir Hepatology 58 2013 902 911
61. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E.Z. Zhang, and J. Spanks et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials Clin Infect Dis 57 2013 221 229
62. C. Wang, J.H. Sun, D.R. O'Boyle 2nd, P. Nower, L. Valera, and S. Roberts et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir Antimicrob Agents Chemother 57 2013 2054 2065
63. A.G. Singal, M.L. Volk, D. Jensen, A.M. Di Bisceglie, and P.S. Schoenfeld A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus Clin Gastroenterol Hepatol 8 2010 280 288
64. A.J. van der Meer, B.J. Veldt, J.J. Feld, H. Wedemeyer, J.F. Dufour, and F. Lammert et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
65. M. Garcia-Retortillo, X. Forns, A. Feliu, E. Moitinho, J. Costa, and M. Navasa et al. Hepatitis C virus kinetics during and immediately after liver transplantation Hepatology 35 2002 680 687
66. M.P. Curry, X. Forns, R.T. Chung, N.A. Terrault, R.S. Brown, and J.M. Fenkel et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation Hepatology 58 2013 314A
67. S. Lens, M. Gambato, M.C. Londono, and X. Forns Interferon-free regimens in the liver transplant setting Semin Liver Dis 34 2014 058 071 10.1055/s-0034-1371011
68. L.M. Forman, J.D. Lewis, J.A. Berlin, H.I. Feldman, and M.R. Lucey The association between hepatitis C infection and survival after orthotopic liver transplantation Gastroenterology 122 2002 889 896
69. M. Prieto, M. Berenguer, J.M. Rayon, J. Cordoba, L. Arguello, and D. Carrasco et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes Hepatology 29 1999 250 256
70. M. Berenguer, A. Palau, V. Aguilera, J.M. Rayon, F.S. Juan, and M. Prieto Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation Am J Transplant 8 2008 679 687
71. A. Blasco, X. Forns, J.A. Carrion, J.C. Garcia-Pagan, R. Gilabert, and A. Rimola et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation Hepatology 43 2006 492 499
72. U.P. Neumann, T. Berg, M. Bahra, D. Seehofer, J.M. Langrehr, and R. Neuhaus et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C J Hepatol 41 2004 830 836
73. A. Potthoff, T. Berg, and H. Wedemeyer Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-alpha2b and ribavirin Scand J Gastroenterol 44 2009 1487 1490
74. D.R. Scott, J.K. Wong, T.S. Spicer, H. Dent, F.K. Mensah, and S. McDonald et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand Transplantation 90 2010 1165 1171
75. E. Gane, and H. Pilmore Management of chronic viral hepatitis before and after renal transplantation Transplantation 74 2002 427 437
76. L.B. Van Wagner, T. Baker, S.N. Ahya, J.P. Norvell, E. Wang, and J. Levitsky Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation J Hepatol 51 2009 874 880
77. J.B. Orens, M. Estenne, S. Arcasoy, J.V. Conte, P. Corris, and J.J. Egan et al. International guidelines for the selection of lung transplant candidates: 2006 update. A consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation J Heart Lung Transplant 25 2006 745 755
78. S. Darke, S. Kaye, and J. Duflou Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes Addiction 101 2006 1771 1777
79. J. Grebely, J.D. Raffa, C. Lai, T. Kerr, B. Fischer, and M. Krajden et al. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents J Viral Hepat 18 2011 32 41
80. H. Hagan, E.R. Pouget, D.C. Des Jarlais, and C. Lelutiu-Weinberger Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place Am J Epidemiol 168 2008 1099 1109
81. P.K. Nelson, B.M. Mathers, B. Cowie, H. Hagan, D. Des Jarlais, and D. Horyniak et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews Lancet 378 2011 571 583
82. C.W. Shepard, L. Finelli, and M.J. Alter Global epidemiology of hepatitis C virus infection Lancet Infect Dis 5 2005 558 567
83. J. Grebely, and G.J. Dore What is killing people with hepatitis C virus infection? Semin Liver Dis 31 2011 331 339
84. N.K. Martin, P. Vickerman, G.R. Foster, S.J. Hutchinson, D.J. Goldberg, and M. Hickman Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility J Hepatol 54 2011 1137 1144
85. N.K. Martin, P. Vickerman, A. Miners, G.R. Foster, S.J. Hutchinson, and D.J. Goldberg et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations Hepatology 55 2012 49 57
86. R. van Heeswijk, A. Vandevoorde, P. Verboven, G. Boogaerts, E. De Paepe, and R. van Solingen-Ristea et al. The pharmacokinetic interaction between methadone and the investigational HCV protease inhibitor telaprevir J Hepatol 54 2011 S491 S492
87. X. Luo, J. Trevejo, R. Van Heeswijk, and V. Garg No significant effect of the HCV protease inhibitor telaprevir on pharmacokinetics and pharmacodynamics of buprenorphine in HCV-negative volunteers Global Antiviral J 7 2011 116 117
88. K. Deterding, N. Gruner, P. Buggisch, J. Wiegand, P.R. Galle, and U. Spengler et al. Delayed vs. immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial Lancet Infect Dis 13 2013 497 506
89. S.M. Kamal Acute hepatitis C: a systematic review Am J Gastroenterol 103 2008 1283 1297
90. M.U. Mondelli, A. Cerino, and A. Cividini Acute hepatitis C: diagnosis and management J Hepatol 42 2005 S108 S114
91. T. Santantonio, J. Wiegand, and J.T. Gerlach Acute hepatitis C: current status and remaining challenges J Hepatol 49 2008 625 633
92. D.B. Strader, T. Wright, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
93. J. Wiegand, E. Jackel, M. Cornberg, H. Hinrichsen, M. Dietrich, and J. Kroeger et al. Long-term follow-up after successful interferon therapy of acute hepatitis C Hepatology 40 2004 98 107
94. C. Camma, P. Almasio, and A. Craxi Interferon as treatment for acute hepatitis C. A meta-analysis Dig Dis Sci 41 1996 1248 1255
95. J.T. Gerlach, H.M. Diepolder, R. Zachoval, N.H. Gruener, M.C. Jung, and A. Ulsenheimer et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance Gastroenterology 125 2003 80 88
96. J.M. Micallef, J.M. Kaldor, and G.J. Dore Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies J Viral Hepat 13 2006 34 41
97. T. Poynard, C. Regimbeau, R.P. Myers, T. Thevenot, V. Leroy, and P. Mathurin et al. Interferon for acute hepatitis C Cochrane Database Syst Rev 1 2002 CD000369
98. H. Hofer, T. Watkins-Riedel, O. Janata, E. Penner, H. Holzmann, and P. Steindl-Munda et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load Hepatology 37 2003 60 64